SGLT2 Inhibitors
Sort by:
Canadian Collaborative Research Network
GLP-1 Agonists: Underused and Underappreciated?
FEATURING
Darren K. Mcguire
- 315 views
- June 13, 2022
- 1
Canadian Collaborative Research Network
CKD: Save the Kidneys, Save the Heart
FEATURING
David Cherney
- 264 views
- June 13, 2022
- 2
ARCH Advanced Revascularization Symposium
First Things First – Pharmacotherapy for HFrEF
FEATURING
Georges Chahoud
- 842 views
- June 2, 2022
- 6
Scripps Health
Diabetes Treatment 2022 and Cardiovascular Risk
FEATURING
Samantha Harris
- 679 views
- June 1, 2022
- 3
ACC 2022 Conference Coverage
ACC 2022: An Overview of SGLT2i and GLP1 RA Use in Cardiovascular Disease
FEATURING
Robert Eckel
- 1,561 views
- May 24, 2022
- 9
University of Colorado Department of Medicine
SGLT2 Inhibitors: Mechanisms of Behind the Mortality Benefit
FEATURING
Amy Li
- 1,303 views
- May 23, 2022
- 5
Heart, Diabetes and Kidney: Make the Link
The New Data and Emerging Therapies Changing the HF Treatment Landscape
FEATURING
Petar Seferovic
- 100 views
- May 18, 2022
Heart, Diabetes and Kidney: Make the Link
Heart Failure, the Picture is Changing: Q&A Discussion
- 59 views
- May 18, 2022
- 1
ACC 2022 Conference Coverage
Hot Topics in Heart Failure ACC.22
FEATURING
Nasrien Ibrahim
- 3,493 views
- April 22, 2022
- 33
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendations for HFrEF and HFmrEF Treatment
FEATURING
Paul Heidenreich
- 18,896 views
- April 21, 2022
- 59
Rita Jermyn
SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease
- 7,985 views
- April 12, 2022
- 52
ACC 2022 Conference Coverage
ACC 2022: SGLT2i in Heart Failure - HFrEF, HFpEF, Class Effect?
FEATURING
Stephen Greene
- 1,447 views
- April 12, 2022
- 10
Texas Cardiovascular Innovations Conference 2021
Heart Failure Management When EF > 40%
FEATURING
Albert Hicks
- 71 views
- March 3, 2022
Texas Cardiovascular Innovations Conference 2021
New Heart Failure Treatment Recommendations
FEATURING
Albert Hicks
- 2,272 views
- March 3, 2022
- 14
Mount Sinai Advanced Innovations in Heart Failure
Heart Failure With Preserved Ejection Fraction: Role of SGLT2 Inhibitors
FEATURING
Juan Badimon
- 946 views
- March 2, 2022
- 10
Mount Sinai Advanced Innovations in Heart Failure
Medical Therapy for Heart Failure in 2022
FEATURING
Anuradha Lala-Trindade
- 1,021 views
- March 2, 2022
- 11
American College of Cardiology
Management of Patients With HFpEF: EMPEROR-Preserved Trial
- 351 views
- February 15, 2022
- 5
Cedars Sinai
SGLT2 Inhibitors: Are They the Modern-Day Statins? Insights from Recent Cardiorenal Metabolic Outcome Trial
FEATURING
Sanjay Kaul,
Milton Packer
- 1,785 views
- February 7, 2022
- 9
13th Orange County Symposium for Cardiovascular Disease Prevention
SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?
FEATURING
Yehuda Handelsman
- 3,406 views
- January 27, 2022
- 15
Piedmont Heart Institute
Cardiometabolic Therapies: GLP-1 RAs and SGLT-2i
FEATURING
Jaime Burkle
- 1,738 views
- January 25, 2022
- 18
16th Annual Mid-Atlantic Hospital Medicine Symposium
Acute Heart Failure and Knowing Medications
FEATURING
Anuradha Lala-Trindade
- 1,243 views
- December 15, 2021
- 17